Table 6.
Known antiviral activities of LL-37.
| Virus | CMV | HSV-1 | HSV-2 | KSHV | VZV | Vaccinia | HAdV A | B | C | D | E | F | HPV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LL-37 | U | Increase IFNB expression, inhibit virus binding | U | Disrupt envelope, prevent viral entrance | U | Disrupt envelope | * | NE | NE | U | NE | * | U |
| Virus (con.) | DENV | HCV | VEEV | Aichivirus A | Echovirus | HRV | Influenza A virus | HPIV | RSV | VHSV | VSV | HIV-I |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LL-37 | Binding to envelope protein | Disrupt enve lope | U | U | * | U | Disrupt envelope, increase neutrophil NET | * | Disrupt envelope, prevent viral exit | * | * | Inhibits reverse transcriptase |
NE: Tested HDP had no effect, U: Antiviral mechanism is undetermined,
Yet to be tested.
Table shows most common result of HDP antiviral test.